Finally, STING silencing significantly inhibited the up-regulation of p-IRF3 and IFN-β expression induced by SGLT2 inhibitor treatment in osteosarcoma cells (Fig. 5h–j), which suggesting that the SGLT2 inhibitor activated the STING/IRF3/IFN-β pathway in osteosarcoma cells. This evidence concerns the gene IRF3 and osteosarcoma.